CNQX

CNQX (FG9065) is a potent and competitive AMPA/kainate receptor antagonist with IC50s of 0.3 μM and 1.5 μM, respectively. CNQX is a competitive non-NMDA receptor antagonist. CNQX blocks the expression of fear-potentiated startle in rats.

Product information

CAS Number: 479347-85-8

Molecular Weight: 276.12

Formula: C9H2N4Na2O4

Synonym:

CNQX 2Na

CNQX Disodium

FG9065 disodium

Related CAS Number:

115066-14-3 (free acid)

Chemical Name:    sodium 6-cyano-7-nitroquinoxaline-2,3-bis(olate)

Smiles: [Na+].[Na+].N#CC1=CC2=NC([O-])=C([O-])N=C2C=C1[N+]([O-])=O

InChiKey: YCXDDPGRZKUGDG-UHFFFAOYSA-L

InChi: InChI=1S/C9H4N4O4.2Na/c10-3-4-1-5-6(2-7(4)13(16)17)12-9(15)8(14)11-5;;/h1-2H,(H,11,14)(H,12,15);;/q;2*+1/p-2

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Soluble in DMSO

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

CNQX (FG9065; 2-5 μM) reversibly blocks the Schaffer collateral and mossy fibre excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition in superfusion of hippocampal slices. CNQX (1-5 μM) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments.

In Vivo:

CNQX (FG9065 disodium; 0.75-3 mg/kg; IP; 20 min before testing) decreased the number of cocaine responses in a dose-dependent manner during the first 15-min cocaine-free interval. The bilateral infusion of CNQX (0.5 or 1.25 μg) into the amygdala or dorsal hippocampus 10 min prior to a retention test partially blocks the expression of stepdown inhibitory avoidance in rats 24 h after training. CNQX causes a complete blockade at a dose of 0.5 μg.

References:

1. Sergeeva OA, De Luca R, Mazur K, Chepkova AN, Haas HL, Bauer A. N-oleoyldopamine modulates activity of midbrain dopaminergic neurons through multiple mechanisms. Neuropharmacology. 2017 Jun;119:111-122. doi: 10.1016/j.neuropharm.2017.04.011. Epub 2017 Apr 9. PubMed PMID: 28400256.
2. Zagrean AM, Spataru A, CeangaM, Zagrean L. The single versus combinatorial effects of MK-801, CNQX, Nifedipine and AP-3 on primary cultures of cerebellar granule cells in an oxygen-glucose deprivation model. Rom J Morphol Embryol. 2014;55(3):811-6. PubMed PMID: 25329107.
3. Gigout S, Louvel J, Rinaldi D, Martin B, Pumain R. Thalamocortical relationships and network synchronization in a new genetic model "in mirror" for absence epilepsy. Brain Res. 2013 Aug 7;1525:39-52. doi: 10.1016/j.brainres.2013.05.044. Epub 2013 Jun 3. PubMed PMID: 23743261.

Products are for research use only. Not for human use.